Following the acquisition of Paige in 2025, Tempus launches its new AI-powered, biomarker prediction solution for digital ...

"The collaboration with Tempus will substantially augment our existing precision oncology capabilities. Northwestern Medicine will now offer next-generation sequencing to patients with earlier-stage ...

Detailed price information for Exact Sciences Cor (EXAS-Q) from The Globe and Mail including charting and trades.

In the first nine months of 2025, Tempus AI Inc. TEM achieved several key regulatory milestones that strengthened its position in AI-driven diagnostics. In September 2025, the company received FDA 510 ...

Tempus and NYU Langone Health have formed a multi-year strategic collaboration to advance cancer research through molecular profiling and data-driven insights. The partnership will support NYU Langone ...

Chicago artificial intelligence giant Tempus AI is showing it's operating in the black after 10 years and growing.

Tempus AI TEM recently started working with leading academic medical centers to broaden access to advanced genomic testing ...